Past Symposia18th Annual Peptide Therapeutics Symposium, October 2023The Structure-function of the Endocrine FGFs: Nature Repeats Itself One Ellipsoid to Rule Them All — Cathelicidin-mimicking Peptoids that are Antiviral, Antibacterial & Antifungal and Well-tolerated in the Airways Harnessing the Power of Molecular Imaging for Precision Medicine: Radiolabeled Peptides, Antibodies, and Everything in Between Activation of the Insulin Receptor by Insulin and Non-insulin Peptide: Application in Human Disease Peptide Therapeutics for the Treatment of Obesity and Type 2 Diabetes Radionuclide Theranostics: Current State and Future Perspectives Pegcetacoplan: The CMC Journey through Development to FDA Approval Advances in Oligonucleotide Delivery to Muscle Using Antibody Oligonucleotide Conjugates (AOCs): Transferrin Receptor 1 (TfR1) Mediated Uptake of AOCs for the Treatment of Muscular Dystrophies Safe and Effective Delivery of Nucleic Acids Using Proteolipid Vehicles Formulated with Fusion-Associated Small Transmembrane Proteins Neuregulin 4 (NRG4) as a New Hormonal Therapy for NASH-related Liver Cancer Establishing a Novel Platform for Discovery of CPPs that Localize in Cytoplasm Amylin: State of the Union The Interplay of Insulin and Glucagon: From Physiology to Pharmacology Computational Design of Novel Peptides for SORT1 and Their Use in Oncology Stealth Editing™ – A Novel Non-Immunogenic In Vivo Gene Editing Technology Development of Efruxifermin, an FGF21 Analog, for Treatment of Nonalcoholic Steatohepatitis (NASH) 17th Annual Peptide Therapeutics Symposium, October 2022Conjugate for the Treatment of Obesity Exploration of Improved MC4R Agonist and Novel MC3R Antagonist Peptides for the Treatment of Obesity A Hundred Years Ago Today the Band Began to Play From Serendipity to Rational Design: Multimodality Therapeutics for Multimorbidity Diseases Development of Differentiated Peptide Therapeutic Products Using an Innovative Formulation Technology Chemical Optimization of the Pancreatic Glycemic Hormones GLP1 Receptor Bias Agonists: The Long and Short of It Ionic Liquids for Delivery of Biologics Oral Inhibitors of the SARS-CoV-2 Main Protease for the Treatment of COVID-19 Engineering Long-acting Relaxin ThP – AZD3427 Discovery and Characterization of Novel Peptides and Small Proteins CryoEM After the Resolution Revolution: Achievements, Developments and Challenges The Next Generation of RaPID System A New Approach to Cancer Therapy with Documented Clinical Effects Invention of Oral PCSK9 Inhibitor from mRNA Display Selection 16th Annual Peptide Therapeutics Symposium, October 2021Design and Evaluation of Synthetic Lipopeptides as Potent Antivirals Development of Next Generation Incretin Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist Peptide The Coming of Age of De Novo Protein Design G Protein-Coupled Receptors: From Structure to Cell Specific Drug Targeting RNA Therapeutics: New Chemical Modalities Becoming a Therapeutic Reality Applications of Covalent Peptide Probes for Imaging of Cancer and Infectious Diseases Peptide-Based Therapeutics: Paving the Way from the Lab to the Clinic Use of Integrin Antagonists to Disrupt Pathological Mechanical Force-Dependent Processes in Fibrosis and Severe Asthma GLP-1 Action-Mechanisms and Future Directions The Use of GLP-1 Receptor Agonists for the Treatment of Parkinson’s Disease Toward Novel Therapeutics via Directed Remodeling of the Gut Microbiome Dasiglucagon, a Next-generation Ready-to-use Glucagon Analog and its Potential Use in Bi-Hormonal Artificial Pancreas Pumps Defining the Melanocortin GPCR System for Non-Opioid Analgesia and Peripheral Diabetic Neuropathic Pain Therapeutic Development Identification, Characterization and Development of Dual Amylin and Calcitonin Receptor Agonists as Novel Drug Candidates Providing Insulin Sensitization and Weight Loss PYY Analogs for the Treatment of Obesity and Type 2 Diabetes Personal Peptide Vaccines Directed at Neoantigens for Patients with Advanced Solid Tumors Recifin A, a Novel and Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I with a Unique Disulfide-bond Topology 15th Annual Peptide Therapeutics Symposium, October 2020Vasopressin: Old Dog. New Tricks. Adrenomedullin Functions at the Maternal-Fetal Interface GEN-009: A Neoantigen Vaccine Based on Autologous Peptide Immune Responses Peptides for Molecular Recognition and Brain Delivery Novel Pairings in the Human Peptide-Receptor Signaling System Deadly Cures: A Spider-Venom Peptide for Treating Ischemic Injuries of the Heart and Brain Building Novel Immune Cell Agonist Anti-Cancer Agents out of Bicycle Parts Chimeric Macrocyclic Peptide Antibiotics Against WHO Priority 1 Gram-Negative Bacteria Targeting both Lipopolysaccharide and BamA Cyclic Cell-Penetrating Peptides: Mechanism of Action and Applications Empowering Peptide Science through Easy 18F-Labeling for PET Imaging and New Stapling Methods Inspired by Natural Product Toxins Novel Therapeutics for Inflammatory Disorders of Pregnancy – Opportunities and Challenges A Peptide Engineering Platform for PEG-FA Stapled Long-Acting Peptide Hormones GI Device Development in a Few Movements Toward Universal Druggability From Farm to Pharmacy: A Strawberry-Derived Solution to Oral Protein Delivery Dual Myristic Acid (Myr) and Trans Activator of Transcription (Tat) Conjugated Peptides: A Potential Platform Technology for Intracellular Cargo Delivery 14th Annual Peptide Therapeutics Symposium, October 2019Speakers Discovery and Characterization of Viral Insulin-like Peptides Elastin-Like Polypeptide Biopolymers Enhance the Pharmacology of Therapeutic Peptides Molecular Mechanisms of Transcriptional Control by Intrinsically Disordered Proteins (aka Peptides) Redesign of Vancomycin for Resistant Bacteria Oral Delivery of Peptides: Present and Future Targeting Intracellular Pathogenic Bacteria with Unnatural Proline-Rich Peptides Mini-Ins: A Minimized, Bioactive Insulin Analog with Fast-Acting Properties Inspired by A Cone Snail Peptide Science 1968-2019, A Retrospective GLP-1@Novo Nordisk: Innovating with Fatty Acid Acylation Evidence of Central Signaling after Administration of Oxytocin at Olfactory and Peripheral Sites GAP Chemistry and Multi-Layer 3D Chirality for the Synthesis of Amines, Amino Acids and Peptides Development of Bifunctional Mu Opioid Receptor (MOR) Agonists/ Delta Opioid A Dual ApoC-II Mimetic-apoC-III Antagonist Peptide for Lowering Plasma Triglycerides Peptide Drug Hunter: Innovation, Integration and Inspiration Potent Antibody-Based Conjugates for Cancer Therapy: From Early Stage Research to a Clinically Discovery of FE 201836, a Short Acting V2R Agonist for the Treatment of Nocturia Structural Basis of Signal Recognition and Regulation at the Full-length Glucagon Receptor Poster Abstracts P01 High Throughput Discovery of Novel Peptides with Biological Function P02 High-Efficiency Solid Phase Synthesis of Peptides and Peptidomimetics with the Liberty Blue P03 Structure-based Drug Design (SBDD) and In Silico Pharmacophore Screening Approaches Combined with Biochemical Validation Enabled the Discovery of Di- and Tetrapeptides Inhibitors of Y-49 and ampC Beta Lactamases P04 The Effects of Novel Myristic Acid Conjugated Protein Kinase C Beta II Activator and Inhibitor Peptides on Phorbol 12-myristate 13-acetate-induced Superoxide Release in Isolated Rat Polymorphonuclear Leukocytes P05 The Effects of Novel Myristoylated PKC Epsilon Peptide Activator and Inhibitor on Nitric Oxide Release in Cultured Human Umbilical Vein Endothelial Cells P06 Spontaneously Cleavable Glycosylated Linkers for Peptides without Suitable Glycosylation Sites P07 Overcoming the Blood-brain-barrier by a Linear 7-mer Peptide, IF7, with Binding Specificity to Annexin A1 in Brain Tumors P08 Illuminating the Assembly and Cellular Interactions of a Trimer Derived from Aβ P09 Chimeric Interleukin-15 Bovine Ultralong Antibody Fusion for Potential Cancer Therapy P10 Suppression of Hypermetabolic Response with a Peptide Targeting a Brown Fat Vascular Marker P11 An Improved Ornithine Turn-Linker for the Stabilization of a Peptide Derived from Aβ17-36 P12 Myristoylated Protein Kinase C Beta II Peptide Inhibitor Exhibits Robust Attenuation of Myocardial Ischemia/Reperfusion Injury in Rats P13 Amphiphilic Tricyclic Peptides: Design, Synthesis, and Biological Evaluation of as Molecular Transporters P14 Searching for Faster and Efficient Solid Phase Peptide Synthesis Methods for Increased Crude Purity in Reduced Time P15 Effects of N-terminal Extensions on the Assembly of Macrocyclic β-sheet Peptides Derived from Aβ(16-36) P16 AutoDock CrankPep: Docking Fully Flexible Large Peptides P17 Distributed Drug Discovery (D3) Synthesis and Testing of Multiple Unnatural Dipeptides Identifies a Subset with Potent Antimicrobial Activity against Pseudomonas aeruginosa (Pa) P18 Hyperdisulfide and Cell-Penetrating Cytoprotective Peptides from Medicinal Plants P19 Evaluation of Structure-Activity Relationship of Cyclic Peptides [W4R4] and Amphipathic Fatty Acyl-Cyclic [W4R4K] as Potential Antibacterial Agents Against Pathogenic Bacteria P20 N-linked Glycosylation Increases Stability and Efficacy of Bivalirudin In Vitro P21 A Dual apoC-II Mimetic-apoC-III Antagonist Peptide for Lowering Plasma Triglycerides P22 Anti-DKK2 D-peptide Inhibitor, One Drug With Multiple Effects on Metastatic Colorectal Cancer Treatment P23 Synthesis and Characterization of a Methylene Thioacetal Human Insulin Analog with Enhanced Stability 13th Annual Peptide Therapeutics Symposium, October 2018Speakers ALRN-6924, a Stapled α-helical Peptide, Reactivates Wild-type p53 by Inhibiting MDMX and MDM2 in in vitro Cell Assays, in vivo animal Models, and in Patients with Cancer Extending the Circulating Half-life of Clot Factors by Conjugation to the Natural Carbohydrate Polymer Heparosan Development of Avexitide for Treatment of Post-Bariatric Hypoglycemia BioChaperone®: A Platform to Improve Solubility and Stability of Therapeutic Proteins and Peptides Peptidic Therapeutics Update Chemically Synthesized Glycosylated Somatostatin Analogs with High Metabolic Stability and Native-like Binding Affinity to all Five Receptor Subtypes Constrained Peptides and Mini Proteins as Novel Therapeutics Targeting p53 Houdini Proteins: Discovery and Applications of Ultrafast Inteins Efficient Chemo-enzymatic Synthesis (CEPS) of Incretin Peptides Glepaglutide, a Novel Long-acting Glucagon-like Peptide-2 Analog for the Treatment of Patients with Short Bowl Syndrome Definition of Endocrine FGF Structure as a Means to Super-agonism Targeting Eph Receptors with Agonist and Antagonist Peptides Alternative Forms and Activities of Human tRNA Synthetases in Biology and Disease Injectable Peptide Gels for the Local Delivery of Drugs Modulating Biological Signaling Through Protein and Small Molecule Design for Therapeutic Purposes About the High Resolution Aβ(1-42) Fibril Structure – and the Orally Available Clinical Stage all-d-enantiometric Peptide PRI-002 that Reverts Cognition Deficits and Decelerates Neurodegeneration in Transgenic AD Mouse Models Identifying and Targeting Tumor Neoantigens Poster Abstracts Early Development of a KISS1/GPR54 Receptor Agonist for Prostate Cancer Design and Synthesis of Brain Penetrant Glycopeptide Analogues of Pituitary Adenylate Cyclase Activating Peptide (PACAP) for the Treatment of Parkinson’s Disease A Nanoformulation Of Lipase With Cellulose Embodied Polypyrrole Functionalized Graphene Oxide Nanocomposite As Promising Nanobiocatalyst: Characterization, Stability Insights And Application Synthesis of a Competitive Stapled Peptide Inhibitor for CHP-NHE1 Protein-Protein Efficient Cytosolic Delivery of Molecular Cargo Mediated by Lipid-specific Endosomal Escape of Supercharged Branched Peptides Insulin Macrocyclization Explores the Relationship Between Conformation and Biological Activity Identification of Microprotein-Protein Interactions via APEX Tagging Antibacterial and Non-cytotoxic Peptide Ferived from the p- BthTX-I Structure-based Design, Synthesis and Evaluation of D-3,3-Diphenylalanine-based Tetrapeptides Inhibitors of Thrombin-activated Platelets Aggregation and Potent Anticoagulants Strategies Toward Optimizing Automated On-resin Disulfide Bond Formation in Disulfide Rich Peptides Leveraging the Knorr Pyrazole Synthesis for the Facile Generation of Thioester Surrogates for use in Native Chemical Ligation Sequence Alignments and Peptide Optimization Discovery of a potential target for the development of therapeutic peptides for preventing bacterial- mediated colorectal cancer Chemical Syntheses of Teixobactin and Structural Analogs Development of a Multi-step Purification of Liraglutide Dissolution of β-sheet Stacking of Peptide Fibrils by Using Intense Mid-infrared Laser Cost Effective Peptide Purification via ZEOsphere DRP Mixed-Mode Chromatography Annotation of Protein-Coding Small Open Reading Frames in the Human Genome Rationally Designing the Most Potent Agonists and Antagonists for the Enterococcus faecalis fsr Circuit: Improving Attenuation of Quorum Sensing-Dependent Pathogenicity BioChaperone Technology Enables the Development of Pramlintide-prandial Insulin Combinations Protein Kinase C Beta Peptide Activator and Inhibitor Regulation of Phorbol 12- myristate 13-acetate (PMA) and N-formyl-L-methionyl-L-leucyl-L- phenylalanine (fMLP) Induced Superoxide Release in Polymorphonuclear Leukocytes (PMNs) Design of Peptide Biomarkers for Complement System Activation Definition of Endocrine FGF Structure as a Means to Super-agonism cGMP Peptide Production from mg to kg with Automation and Microwave-Assisted Heating Fluorogenic Amino Acids and Their Potential as Real-Time Probes for Protein Synthesis Discovery of Novel Albumin Binding Peptides Using Rational Design and Phage Display Using N-linked Glycosylation to Stabilize Bivalirudin Novel MC2R Antagonists Decrease Cortisol in Primary Human Adrenal Cortical Cells and Corticosterone in an in vivo Model of Hypercortisolism Establishing a Cell-Free Vibrio natriegens Expression An Efficient Method for the Expression and Purification of Aβ(M1–42) and N-terminal Cysteine The Expression and Characterization of Disulfide-Bond Stabilized Aβ Oligomers Exploration of Mechanism of Action of Luminate®, a Therapeutic Peptide for Blinding Retinal Disease 12th Annual Peptide Therapeutics Symposium, October 2017Cellular Manipulation through Cell Penetrating Peptide-Loaded Exosome Transfer A Novel One-Pot Synthesis Strategy for Bicyclic Peptide Assembly ORBIT Peptide Display—High throughput Selection of Peptides with Biological Function Efficient Cell Aelivery and Lipid-specific Endosomal Escape by Aupercharged Peptides Effect of a Fusion Peptide by Covalent Conjugation of a Mitochondrial Cell-penetrating Peptide and a Glutathione Analog Peptide MOE Coupled with AutoDock Vina Molecular Docking and Virtual Screening Empowered Discovery of Tetrapeptides Inhibitors of Y-49 β-Lactamase Genetically Encoded Discovery of Chemically-Modified Peptides Scaffold-based Citrullinated Peptides for Inhibition of Autoantibodies in Rheumatoid Arthritis Towards Mild and Selective Incorporation of Freidinger Lactams into Expressed Peptides GUB06-046, a Novel Secretin/GLP-1 Co-Agonist, Decreases Food Intake, Improves Glycemic Control and Preserves Beta Cell Mass in db/db Mice Machine Learning Techniques for Peptide Optimization from Sequence Information Fast Synthesis of 84-mer Human Parathyroid Hormone for the Study of Osteoporosis and Hypoparathyroidism A Novel Tri-Peptide Elicits Cardioprotective Effects in Myocardial Ischemia/Reperfusion Injury by an Opioid Receptor Mechanism Designing Cell-material Interactions by Controlling the Chemistry of the Surface of Degradable Porous Scaffolds Modulation of Quorum Sensing in Streptococcus pneumoniae; An Alternative Approach to Antimicrobial Therapy Characterizing the Impact of the Highly Endosomolytic Cell-Penetrating Peptide, dfTAT, on Investigation of Novel Cyclic Peptides for Preferential Binding to Melanocortin 4 Receptors Mapping Membrane Activity in Undiscovered Peptide Sequence Space Using Machine Learning On the Effects of Acylation of Cell-penetrating Peptides in Nucleic Acid Delivery In Vitro and In Vivo Effective Prediction of Long-term Stability and Aggregation Propensity of Proteins via Differential Scanning Calorimetry (DSC) Evaluation of Apelin-13 Analogues as Antidiabetic Therapeutics Myristoylated Protein Kinase C Epsilon Peptide Inhibitor Reduces Infarct Size and Improves Cardiac Function Following Myocardial Ischemia/Reperfusion (I/R) CPP and Small Molecule Synergy Enhances Endosomal Escape and Cytosolic Delivery in Live Cells Optimizing Peptide Manufacturing on the Small Scale and its Application in the Rapid Development of New Personalized Medicines Novel Therapeutic Peptides Targeting Matricellular Signaling in Currently Untreatable Fibrotic Disease and Cancer Improved Florescent Amino Acids For In Situ Labeling of Bacterial Cell Walls Development of a New Method on Npys-based Disulfide Bond Formation for the Preparation of Bioactive Cyclic Disulfide Peptides Discovery of Selective Hexapeptide Agonists to Human NMUR1 and NMUR2 Highly Efficient Synthesis of Therapeutic Macrocyles by Ligases Computational Design and Experimental Characterization of Peptides Intended for pH-Dependent Membrane Insertion and Pore Formation Plasma Protein Binding Analysis of Peptides with a Novel Single-compartment Mass Spectrometry Assay Targeting Quorum Sensing in Streptococcus Pneumoniae: An Alternative Antibacterial Approach N-linked Glycosylation Prevents Deamidation of Glycopeptide and Glycoprotein Structure-Based Design, Synthesis and Evaluation of Constrained Seven Membered Ring-Containing Tetrapeptides Lead to Selective Human Melanocortin 1 Receptor 11th Annual Peptide Therapeutics Symposium, October 2016Asprosin, a Fasting-Induced Glucogenic and Orexigenic Protein Hormone Tailoring Peptides for less Frequent Dosing and Non-invasive Delivery Non- Peptide GLP-1 Receptor Agonists; From Idea to Medicine Structural Elucidation of Ligand Binding Sites in Class B GPCRs and their Application in Drug Discovery Selective Inhibition of Cytokines with Peptide Therapeutics: A Unique Alternative to Conventional MAB and JAK Inhibitor Approaches for Cytokine Modulation Peptide-based Strategies to Treat Inflammatory and Autoimmune Diseases: From the Peptide P140 to Lupuzor™ Innovation by Evolution: Expanding the Enzyme Universe Novel Synthetic Strategies for Insulin and Related Peptides AB103: Host-Oriented Therapeutics to Control Life Threatening Infections Engineering Potent and Selective Inhibitors of Nav1.7 Sodium Channel Taregting Novel Polysaccharide-binding Proteins to Block Tissue Fibrosis TLQP-21 and C3aR1, a Novel Ligand/Receptor Target for Lipolysis and Obesity Discovery and Clinical Development of Elamipretide Unlocking the Mysteries of Amyloid Diseases with Macrocyclic β-Sheet Peptides Endocrine FGFs and Structure-Activity-Relationship New Therapeutics from the Human Microbiome: Discovery of Novel Proteins and Peptides for the Treatment of Gastrointestinal Barrier Related Disorders Chemo-enzymatic Peptide Synthesis (CEPS): A Generally Applicable, Traceless Ligation Technology for the Synthesis of Peptide-to-peptide and Peptide-to-protein Conjugates InGell® – Injectable Drug Depots for Short and Mid-term Release of Soluble and Non-soluble API’s Errata located at the end of the Symposium PDF 10th Annual Peptide Therapeutics Symposium, October 2015Building Better Medicines: Translational Research in the 21st Century An Integrated View of the Adipocyte: From Feast to Famine Oral Peptide Delivery: Deciphering the Reality from the Hype Oral Inhalation – A Simple Approach to Biologics Delivery ITCA 650 (Exenatide Delivered Continuously via a Matchstick-Size Subcutaneous MICROCOR® Transdermal System: Technology Overview and Clinical Status Activity-based Proteomics – Applications for Enzyme and Inhibitor Discovery Molecular Targets for the Effects of Bariatric Surgery on Obesity and Diabetes Harnessing Chemistry and Glycoproteins to Discover Novel Targets for Cancer Engineered Cystine Knot Peptides: A New Class of Tumor Targeting Agents Phage Selection of Bicyclic Peptides for Application as Therapeutics Kisspeptin and its Short-length Agonist Analogues: Discovery and Development Phage-display Derived Peptidic Inhibitors of PCSK9 for LDL Cholesterol Lowering Improved Chemical and Physical Stability in Liquid Formulations – How to Design Selepressin, a Selective hV1a Agonist for the Treatment of Hypotension in Septic Shock Addressing the Challenges with the Discovery and Development of Peptide NA-1: From Bench to Bedside – A Novel Peptide Therapeutic for the Treatment of Relamorelin, a Ghrelin Agonist for the Treatment of Diverse Functional 9th Annual Peptide Therapeutics Symposium, October 2014Multiselective Peptides for the Treatment of Metabolic Diseases by Cristina Rondinone, Ph.D., Vice President, Research and Development, Head Cardiovascular/Metabolic Diseases iMED, Medimunne Peptide Agonists of Incretin Receptors Are High Priority Candidates in the Search for the First Effective Treatments of Alzheimer’s Disease by Konrad Talbot, Ph.D., Associate Professor, Department of Neurosurgery, Cedars-Sinai Medical Center Continuous Glucose Monitoring: Technology that will Bridge the Gap until there is a Cure for Type 1 Diabetes by Steven Edelman, M.D., Professor of Medicine, University of California San Diego, Veterans Affairs Medical Center , Founder and Director, Taking Control of Your Diabetes 501(c)3 Peptide Therapeutics: A New Golden Age by Richard A. Houghten, Ph.D., Founder, President & CEO, Torrey Pines Institute for Molecular Studies New Physiology and Pharmacology of the Melanocortin-4 Receptor by Roger D. Cone, Ph.D.,Professor and Chair, Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center Chemoenzymatic Approaches in Amide-to-amide Peptide Ligation by James P. Tam, Ph.D. , Professor, Herbalomics and Drug Discovery, School of Biological Sciences, Nanyang Technological University Hepcidin and Minihepcidins: From Mechanistic Studies to Therapeutic Peptides by Tomas Ganz, Ph.D., M.D., Professor of Medicine and Pathology, University of California, Los Angeles Discovery of Functional Ligands and Materials from Genetically-encoded Libraries of Chemically-modified Peptides by Ratmir Derda, Ph.D.,Assistant Professor, Department of Chemistry and Alberta Glycomics Centre, University of Alberta Using the Endosome Escape Trap to Discover Phylomer Peptides which more Efficiently Deliver Cargoes to the Cytoplasm by Paul Watt, D.Phil., Chief Scientific Officer, Phylogica Ltd Danegaptide – Potential First and Best in Class Peptide Medicine for Prevention of Myocardial Reperfusion Injury by Rie Schultz Hansen, MSc, Ph.D. , Principal Scientist, Zealand Pharma A/S Arylomycin Antibiotics by Floyd E. Romesberg, Ph.D., Assistant Professor, Department of Chemistry The Scripps Research Institute Novel Peptide Therapeutics Targeting Key Intracellular Signaling Pathways of Cancer Stem Cells by Jörg Vollmer, Ph.D., Managing Director and Chief Executive Officer, Nexigen GmbH Peptide Antagonists of the Inflammatory Response Enhanced by the Antimicrobial Peptide LL-37 by Cheng Kao, Ph.D. , Director of Biotechnology and Professor, Department of Molecular & Cellular Biology, Indiana University Integrated Triple Gut Hormone Action Broadens the Therapeutic Potential of Endocrine Biologics for Metabolic Diseases by Brian Finan, Ph.D. Division Head, Helmholtz Zentrum Munich 8th Annual Peptide Therapeutics Symposium, October 2013The Structural and Energetic Basis of Carbohydrate–Polypeptide Stabilizing Interactions Within Enhanced Aromatic Sequons in Protein Native States by Jeffery W. Kelly, The Scripps Research Institute Developing IMS-MS Techniques as a means of Following Structural Transitions of Biopolymers in Solution by David E. Clemmer, Indiana University Half-Life Extension Through HESylation® by Martin Meyer, Fresenius Kabi Deutschland GmbH Long-acting Release of Drug Peptides by in situ Gelling FluidCrystal® Injection Depot by Fredrik Tiberg, Camurus AB The Transdermal Delivery of Peptides and other Biotherapeutics by Frank Tagliaferri, 4P Therapeutics Structural Insights into HIV, Influenza & HCV Antigen Design by Ian A. Wilson, The Scripps Research Institute How Insulin Binds: Structure of a Micro-receptor Complex and Implications for Analog Design by Michael A. Weiss, Case Western Reserve University Mimicry of Hormone Recognition Surfaces with Peptidic Foldamers by Samuel H. Gellman, University of Wisconsin, Madison ShK-186, a Peptide Inhibitor of Kv1.3 Potassium Channels as Therapy for Autoimmune Diseases and Metabolic Syndrome by K. George Chandy, University of California, Irvine The Tale of Two Peptides Rescuing a Company in Distress by Roger J. Garceau, NPS Pharmaceuticals, Inc. Towards Optimized Utility of Proteasome Inhibitors with Peptide Epoxyketones by Christopher J. Kirk, Onyx Pharmaceuticals, Inc. Direct Selection of Highly Potent Cyclic Peptidomimetics from In Vitro Display Libraries by Douglas A. Treco, Ra Pharmaceuticals, Inc. Development of Serelaxin for Acute Heart Failure by Dennis Stewart, Corthera Inc., Novartis Pharmaceuticals Corp. SOM230: A New Therapeutic Modality for Cushing’s Disease by Ian Lewis, Novartis Institutes of Biomedical Research PeptiDream’s PD Platform: Innovative Peptide Discovery Platform by Patrick C. Reid, Peptidream Inc. Design of Peptide Therapeutics Exhibiting Dual Pharmacology and Extended Duration of Action by Soumitra Ghosh, Amylin Pharmaceuticals LLC The Development of BA058, a Novel Peptide, for the Treatment of Osteoporosis by Gary Hattersley, Radius Health, Inc. 99mTc-Galacto-RGD2: A novel 99mTc-Labeled Cyclic RGD, Peptide Dimer Useful for Tumor Imaging by Michael Pennington, Peptides International, Inc. 7th Annual Peptide Therapeutics Symposium, October 2012Chemoselective Strategies for the Synthesis of Complex Assemblies of Peptide by Cell-penetrating Peptides with Intrinsic Biological Activity by Francesca Milletti, Ph.D., Head, Cheminformatics & Statistics, Roche Pharmaceuticals Peptide Macrocyclization Enabled by Amphoteric Molecules by Andrei K. Yudin, Ph.D., Professor, Davenport Research Laboratories, Chemistry Department, The State of Pharmaceutical Innovation by Bernard Munos, MBA, Founder, InnoThink Center for Research in Biomedical Innovation Design of Therapeutics that Act on Membranes and Membrane Proteins by Bill DeGrado, Ph.D., Professor, Department of Pharmaceutical Chemistry; Investigator, Cardiovascular Gut-peptide Based Poly-pharmacy for the Treatment of Obesity & Diabetes by Matthias Tschöp, M.D., Alexander-von-Humboldt Professor; Director, Institute for Diabetes and Omontys: Beating the Odds in the Journey of a Drug from Bench to Bedside Identification and Characterization of KAI-4169, A Novel Peptide for the Treatment Stapled Peptide Drugs: Translation to the Clinic by Tomi K. Sawyer, Ph.D., Chief Scientific Officer and Senior-Vice President, Drug Discovery and Innovative LY2605541, a Novel Long-acting Basal Insulin by Mel Prince, M.D. Senior Medical Director, Lilly Diabetes, Eli Lilly and Company NMDA Receptor Modulating Peptides with Therapeutic Potential: From Monoclonal Antibodies to the Creation and Development of GLYX-13 by Joseph R. Moskal, Ph.D., Professor and Director, The Falk Center for Molecular Therapeutics, McCormick School of Engineering and Applied Sciences, Dept. of Biomedical Engineering, Northwestern University XEP-018: A New Myorelaxant Peptide Lead Compound from the Venom of the XTENylation Offers a Biodegradable Alternative to PEGylation by Volker Schellenberger, Ph.D., Chief Scientific Officer, Amunix, Inc. Tunable Half-life Extension of Therapeutics by Controlled Chemical Release from Development of Modified Human Serum Albumins for Peptide and Protein Half-life Extension: Towards Monthly Dosing by Mark Perkins, Ph.D., Customer Solutions Manager, Novozymes Biopharma UK Ltd. Clinical Development of a Novel PTH Analog for the Treatment of Osteoporosis with an 6th Annual Peptide Therapeutics Symposium, October 2011Discussion about factors driving R&D funding today Development of a Long-acting C-peptide (ErsattaÔ) by James Callaway, Ph.D. President and CEO, Cebix Incorporated Long Acting Y2R Peptide Mimetic as a New Generation Therapeutic Agent for the Management of T2D by Waleed Danho, Ph.D., Distinguished Research Leader, Hoffmann- La Roche Inc. Somatostatin-Dopamine Chimeric Molecule for Potential Treatment of Pituitary Adenomas and Neuroendocrine Tumors by Jesse Z. Dong, Ph.D., Director, Peptide Therapeutics Foundation, Vice President, Compound Discovery, Ipsen Targeting Protein Therapeutics Across the Blood-Brain Barrier with Molecular Trojan Horses by William M. Pardridge, Ph.D., Distinguished Professor of Medicine, University of California, Los Angeles Neuropeptidomics: From the Discovery of New Neuropeptides to the Elucidation of their Functions by Jonathan Sweedler, Ph.D., Professor of Chemistry, James R. Eiszner Family Chair, University of Illinois, Urbana-Champaign Comparative Peptidomic Analysis for Functional Discovery of Neuropeptides by Lingjun Li, Ph.D., Professor, School of Pharmacy and Department of Chemistry, University of Wisconsin High Resolution Mass Spectrometry-Based Profiling of Secreted Peptides for Drug Discovery by Steven Taylor, Ph.D. EPiC Technology: Using Peptide to Physiologically Cross the BBB by Jean Paul Castaigne, M.D., MBA, President and CEO, AngioChem Endogenous Peptides to Safely Enhance the Delivery of (peptide) Drugs to the Brain by Willem van Werperen, MSc, MBA, CEO, to-BBB Enhancing CNS Uptake of Biologics through Molecular Engineering by Ryan Watts, Ph.D., Associate Director, Head of Neurodegeneration Labs, Department of Neuroscience, Genentech, Inc. NPY2R Selective Peptide Agonists for the Treatment of Obesity: Balancing Efficacy, Time Action and Cardiovascular Profile by Jordi Alsina, Ph.D., Senior Research Scientist, Eli Lilly & Company Development Of CR845, a Novel, Peripherally-Acting Peptidic Kappa Opioid Agonist, for the Treatment of Postoperative Pain by Derek Chalmers, Ph.D., D.Sc., President & CEO, Cara Therapeutics, Inc. ZYPH0907: A Novel Orally Active PTH1R Agonist for Treatment of Osteoporosis by Mukul Jain, Ph.D.,Senior Vice President, ZydusResearch Center 5th Annual Peptide Therapeutics Symposium, October 2010Venture Capital panel discussion: Attractive Financing Structures for Emerging Biotechnology Companies. Chemical Synthesis in the Development of Protein Therapeutics by Stephen B.H. Kent, Ph.D., Professor, Department of Chemistry, University of Chicago Chemically Programmed Immunity: Making Peptides Drugs and More by Carlos Barbas III, Ph.D., Janet and Keith Kellogg II Chair in Molecular Biology Professor, Department of Molecular Biology, The Scripps Research Institute Tumor-penetrating Peptides in Targeted Tumor Treatment by Erkki Ruoslahti, M.D., Ph.D., Distinguished Professor, Sanford-Burnham Medical Research Institute Glioblastoma: Cancer Stem Cells and Reprogramming by Inder Verma, Ph.D., Professor, Irwin and Joan Jacobs Chair in Exemplary Life Science, Laboratory of Genetics and American Cancer Society Professor of Molecular Biology, Salk Institute for Biological Studies From Combinatorial Chemistry to Nanoparticles to Cancer Imaging and Therapy by Kit Lam, M.D., Professor and Chief, Hematology and Oncology, University of California Davis Cancer Center Protein Engineering: A Key Innovation Path for Novel Biopharmaceuticals by Thomas Bumol, Ph.D., President, Applied Molecular Evolution & Vice President Biotechnology, Lilly Research Laboratory Early Clinical Development of Novel Biologics by Richard Jones, M.D., Chief Medical Officer, Syntaxin Ligand-receptor Fusions for the Generation of Long-acting Biopharmaceuticals by Richard Ross, M.D., Chief Scientific Officer and Director, Asterion Antibody Drug Conjugates: Current and Future Developments by Hans-Peter Gerber, Ph.D., Senior Director Pfizer Enhancing the Activities of Monoclonal Antibodies for Cancer Therapy by Peter Senter, Ph.D., Vice President Chemistry, Seattle Genetics New Horizons in Protein Medicinal Chemistry Enabled with an Expanded Genetic Code by Ho Sung Cho, Ph.D., Chief Technical Officer, Ambrx Inc.
4th Annual Peptide Therapeutics Symposium, November 2009Update on development trends for peptide therapeutics by Janice M. Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development. New Targets and Targeting Mechanisms for Contrast Agents and Therapeutics by Roger Tsien, Ph.D., HHMI Investigator& 2008 Nobel Laureate Chemistry, Professor Pharmacology, Chemistry and Biochemistry, UCSD. NMR structural studies of drug receptors in membranes by Stanley Opella, Ph.D., Professor Chemistry and Biochemistry & Director Nuclear Magnetic Resonance Resource Lab, UCSD. Peptide transduction domain mediated delivery of macromolecules; Tackling the siRNA delivery problem by Steven F. Dowdy, Ph.D., HHMI Investigator & Professor Cellular and Molecular Medicine, School of Medicine, UCSD Peptide inhibitors of protein-protein interactions; From rational design to the clinic by Daria Mochly-Rosen, Ph.D., Professor, Chemical and Systems Biology & Senior Associate Dean for Research, School of Medicine, Stanford University. Stapled helical peptides: A new drug modality by Noriyuki Kawahata Ph.D., Senior Principal Scientist Chemistry, Aileron Therapeutics. Clinically validated inhibitors of intracellular protein interactions by Stephen D. Harrison, Ph.D., Senior Vice President, Research, Kai Pharmaceuticals. Pepducins – Novel mediators of GPCR signaling by Stephen Hunt, Ph.D., Senior Vice President, Discovery Research, Ascent Therapeutics. Linaclotide: A potential therapy for IBS-C by Mark G. Currie, Ph.D., Senior Vice President, R&D & CSO, Ironwood Pharmaceuticals Inc. Non-Invasive systemic delivery of peptides with high bioavailability by Edward T. Maggio, Ph.D., CEO & Director, Aegis Therapeutics.
3rd Annual Peptide Therapeutics Symposium, October 2008CovX-Body Biotherapeutics: From Concept to Applications by Joel Desharnais, Ph.D. Senior Scientist, CovX Sustained Release of Peptides Using Microencapsulation and the Development of Long Acting Exenatide by Paul Herbert, Vice President Process Development Alkermes , Inc. Engineering Kunitz Domains Using Phage Display by Andrew E. Nixon, Ph.D., Vice President, Lead Discovery and Biochemistry, Dyax Corporation Preformed Conjugate-Drug Affinity Complex (PC-DAC™) Technology by Martin Robitaille, Ph.D., Director, Peptide Chemistry, Conjuchem Biotechnologies, Inc. Trends in the Clinical Development and Approval of Synthetic Peptides by Janice Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development
2nd Annual Peptide Therapeutics Symposium, November 2007Building, Understanding and Leveraging a Peptide Library by Michael Hanley, Ph.D., Vice President Discovery Research, Amylin Pharmaceuticals Application of Chemical Biotechnology to the Optimization of Protein Therapeutics by Richard Dimarchi, Ph.D., Professor, Department of Medicinal Chemistry, Indiana University Degarelix: a novel GnRH antagonist for the treatment of prostate cancer by Per Cantor, M.D., Ph.D., Senior Vice President Clinical and Non-Clinical Development, Ferring Pharmaceuticals KL-4 Surfactant – Form to Function by Charles Cochrane, M.D., Professor, Department of Immunology, The Scripps Research Institute The Commercialization of Fuzeon® API by Brad DeHoff, Ph.D., Technical Manager, Roche Colorado Corp. The Beta Cell Hormone Amylin: Discovery and Clinical Application by Andrew Young, M.D., Ph.D., Vice President , Senior Research Fellow, Amylin Pharmaceuticals “Ynot Y2 and Y4 Peptide Agonists for Treatment of Diabetes and Obesity?” by Thue Schwartz, M.D., CSO, 7TM Pharma, University of Copenhagen Oxyntomodulin or Products of the PYY Preproglucagon gene by Steve Bloom, M.D., Professor of Medicine, Imperial College, London
1st Annual Peptide Therapeutics Symposium, November 2006Medicinal Chemistry of Peptide Hormones by Victor Hruby, Ph.D., Regents Professor of Chemistry, University of Arizona GnRH: a Peptide for All Seasons by Robert Millar, Ph.D., Director, MRC Human Reproductive Sciences Unit, Ardana Desmopressin, a Selective Antidiuretic Analog of Vasopressin by Jens Peter Norgaard, Ph.D., CSO, Urology, Ferring Pharmaceuticals History of the Development of Byetta: The Vicissitudes of Drug Development in Biotechnology by Alain D. Baron, Ph.D., Sr. Vice President, Research, Amylin Pharmaceuticals Clinical Applications of the GLP-2 Analogue Teduglutide by Derek Chalmers, Ph.D., President & CEO, Cara Therapeutics Current Status of Methods for Large-Scale Production of Peptides Michael Verlander, Executive Vice President, Ph.D., Polypeptide Laboratories, Inc.
Symposium 1-5For more information regarding Symposiums 1-5, please contact us. |
|
|
